Quantum BioPharma Submits IND Application To FDA For Lucid-21-302, Its New Drug Candidate For Treatment Of Multiple Sclerosis

Quantum BioPharma Ltd. has submitted an Investigational New Drug (IND) application to the FDA for its new drug candidate, Lucid-21-302, aimed at treating multiple sclerosis. This submission is a key step towards initiating a Phase 2 clinical trial for the first-in-class therapeutic treatment targeting demyelination, marking a significant advancement in the company's clinical development pipeline and its strategic growth in the global neurological market.